---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-018988"
form_type: "8-K"
ticker: "DMRA"
cik: "0001800315"
company_name: "Damora Therapeutics, Inc."
filed_at: "2022-09-29T23:59:59+00:00"
generated_at: "2026-06-23T06:46:42.539899+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Galecto reports GB2064 reduces bone marrow fibrosis in 4 of 5 evaluable myelofibrosis patients

## Summary
- Four of five evaluable patients on GB2064 achieved ≥1-grade reduction in collagen fibrosis over 6 months.
- All four fibrosis responders showed stable hemoglobin, WBC, platelets, and spleen volume; no transfusions needed.
- Two patients entered extension phase due to clinical benefit as assessed by treating physician.
- No treatment-related SAEs in the 5-patient evaluable group; one possible SAE (fall) in entire 16-patient trial.
- Company expects top-line results from GULLIVER-2 liver cirrhosis trial in coming weeks.

## SEC filing metadata
- accession: 0000950170-22-018988
- form_type: 8-K
- ticker: DMRA
- cik: 0001800315
- company_name: Damora Therapeutics, Inc.
- filed_at: 2022-09-29T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1800315/000095017022018988/0000950170-22-018988-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1800315/000095017022018988/glto-20220929.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-018988
- JSON: https://secwatch.observer/filing/0000950170-22-018988.json
- Plain text: https://secwatch.observer/filing/0000950170-22-018988.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.